41,968 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Tema Etfs LLC

Tema Etfs LLC bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 41,968 shares of the company's stock, valued at approximately $1,735,000. Tema Etfs LLC owned about 0.09% of Mirum Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of MIRM. Janus Henderson Group PLC raised its holdings in Mirum Pharmaceuticals by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,581,642 shares of the company's stock valued at $189,481,000 after acquiring an additional 101,358 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Mirum Pharmaceuticals by 10.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company's stock valued at $58,831,000 after purchasing an additional 138,623 shares during the last quarter. Geode Capital Management LLC lifted its position in Mirum Pharmaceuticals by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock worth $39,016,000 after buying an additional 7,147 shares in the last quarter. Clearbridge Investments LLC lifted its position in Mirum Pharmaceuticals by 2.0% during the fourth quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock worth $37,518,000 after buying an additional 18,217 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its stake in Mirum Pharmaceuticals by 5.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 782,354 shares of the company's stock worth $32,350,000 after buying an additional 40,986 shares during the last quarter.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 27,279 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the transaction, the chief executive officer now owns 138,641 shares in the company, valued at $6,129,318.61. The trade was a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Jolanda Howe sold 57,606 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the sale, the senior vice president now owns 4,841 shares in the company, valued at approximately $214,698.35. This trade represents a 92.25% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,764 shares of company stock worth $4,109,161. 14.36% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Trading Down 2.3%

Shares of Mirum Pharmaceuticals stock traded down $1.03 on Wednesday, reaching $44.31. The company had a trading volume of 322,751 shares, compared to its average volume of 524,211. The firm's 50 day moving average price is $42.97 and its two-hundred day moving average price is $44.55. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.83 and a 52-week high of $54.23. The firm has a market cap of $2.19 billion, a PE ratio of -21.94 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. During the same quarter last year, the firm earned ($0.54) EPS. The firm's revenue for the quarter was up 61.2% on a year-over-year basis. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on MIRM. JMP Securities raised their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research note on Friday, May 9th. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday. Finally, Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $60.73.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.